Extra-gastrointestinal stromal tumor (EGIST) is a special type of gastrointestinal stromal tumor, which has similar biological characteristics to its counterpart, and occurs outside the gastrointestinal tract. It was identified first by Miettinen et al. [1] , and named by Reith et al. [2] . The incidence of EGIST is extremely low, and so far there is no detailed epidemiological figure. To the best of our knowledge, EGIST has been commonly reported in the mesentery, omentum or retroperitoneum [1] [2] [3] [4] , and sporadically in the pleura [5] , pancreas [6] [7] [8] [9] [10] [11] [12] , liver [13] [14] [15] [16] [17] [24, 25] . Most existing studies of EGIST are case reports, lacking enough information to clarify the disease; thus it is very difficult to establish helpful guidelines for clinicians. It is very common that EGIST is misdiagnosed for other tumors. Herein, we report an extra-gastrointestinal stromal tumor of the liver, which was diagnosed by ultrasound-guided fine needle aspiration cytology (US-FNAC), and review the literature, so as to help understand EGIST better.
Due to the patient's condition, hepatectomy could not be performed, and a US-FNAB from the liver mass was taken. Histologically the tumor consisted of spindle cells with pleomorphic nuclei, commonly vacuoles beside the nuclei and abundant intercellular collagen (Figures 2 A-B) . Immunohistochemical analysis revealed that the spindle cells were positive for CD117 (Figure 3 , while they were negative for CK (Figure 3 C) and S-100 (figure not shown). All these results indicated that the diagnosis was extra-gastrointestinal stromal tumor. The tumor's mitotic activity could not be evaluated because of the small amount of examined material. KIT gene mutation analysis was not performed due to its non-availability at our institute.
Zhou-Yu Li, Qi-Lian Liang, Guo-Qiang Chen, Yuan Zhou, Qiu-Long Liu We advised the patient to take imatinib mesylate (Glivec), but he refused because of financial problems, and was discharged 13 days later.
Gastrointestinal stromal tumor (GIST) is a common tumor of the gastrointestinal tract, which mainly occurs in the stomach. When this kind of neoplasm develops outside the gastrointestinal tract, it is defined as EGIST. Metastasis of GIST to the liver is very common, while primary GIST of the liver is extremely rare. To the best of our knowledge, only 5 cases of primary hepatic EGIST have been reported previously in English [13] [14] [15] [16] [17] (Table I ). There is a distinct male predominance, and their age ranges from 17 to 79 years, average 47.7 years. The majority have a large tumor size, only one under 10 cm. Four of 6 cases have a spindle cell type. Both CD117 and CD34 have only one case that is negative. The mitotic rate and outcome are hard to analyze. Due to the particularity of hepatic EGIST, it should be diagnosed differentially with primary or metastatic poorly differentiated carcinoma, angiomyolipoma, leiomyosarcoma, or malignant melanoma. HMB-45 and PKCθ were recommended in immunohistochemical analysis, so as to exclude the mimics mentioned above [17] .
US-FNAC is the quickest and least painful way to obtain an accurate tissue diagnosis of a lump anywhere in the body. There are three steps in US-FNAC: firstly, the position, size and adjacent structure of the lesion are evaluated by ultrasound; secondly, two or more samples are taken with a 23-gauge or 25-gauge needle; lastly, the obtained samples are stained and examined by a pathologist. It has multiple advantages compared to open biopsy, which is not only inexpensive and minimally invasive but is also performed simply and easily. Furthermore, it allows surgery or neoadjuvant treatment to be performed expeditiously with a confirmed preoperative diagnosis. An accurate diagnosis is made with the combination of clinical examination, radiology and FNAC. Although EGIST is rare, it also could be diagnosed by this technique. Rao et al. [26] reported a case and reviewed three cases of pancreatic EGIST, which were diagnosed by US-FNAC. Luo et al. [15] showed that there was no exception on hepatic EGIST. The present case revealed that the biopsy samples were enough for cytological analysis, although the mitotic rate could not be determined.
In order to understand EGIST more clearly, we have reviewed several quite large studies [1] [2] [3] [4] [27] [28] [29] [30] (Table II) published recently. When these data are summarized together, some similarities can be seen distinctly. The incidence of EGIST is 5%-7% of cases of GIST [4, 28] , with a female predominance (64.9%, 98/151), and the most frequent lesion sites are the mesentery, omentum and retroperitoneum [1] [2] [3] [4] . The median age is 58.5 years, which is simi-Zhou-Yu Li, Qi-Lian Liang, Guo-Qiang Chen, Yuan Zhou, Qiu-Long Liu lar to jejunal and ileal GISTs (59 years) [31] . Due to EGIST being outside of the gastrointestinal tract, there are no common symptoms such as bleeding or obstruction. Furthermore, the abdominopelvic cavity and retroperitoneum have enough room for a neoplasm to grow. Thus most of the cases presented a tremendous mass when first detected, with median size of 13.5 cm. Whether the tumor size is a prognostic factor or not, it should be taken into account. Reith et al. [2] found that there were no significant differences between large (> 10 cm) and small (≤ 10 cm) tumors in outcome. The cell morphological pattern of EGIST is predominantly spindle (71 cases) or epithelioid (54 cases). Three studies [1] [2] [3] , in which the number of patients was more than 20, were in accord with the figure. Spindle cell EGIST should be diagnosed differentially with smooth muscle tumors, schwannoma, solitary fibrous tumor and sarcomatoid carcinoma, while epithelioid EGIST should be diagnosed differentially with metastatic melanoma, carcinoma, clear cell sarcoma and epithelioid hemangioendothelioma [32] . More than one third (55/135) of cases displayed a mitotic index more than 5 per high-power field (HPF). Yamamoto et al. [3] revealed that a high mitotic rate (≥ 5/50 HPF) had significantly shorter disease-specific survival than a low rate (< 5/50 HPF) (p = 0.015). Almost 100% were positive for CD117 [2] [3] [4] 29] . We think that it may be because most of them are retrospective studies. The patients were used to being easily misdiagnosed with other diseases. With this type of issue, CD117 was recommended as a selection criterion. CD117-negative tumors should be taken seriously; it still cannot exclude EGIST. Demetri et al. [32] recommended using DOG-1 as a candidate when CD117 immunostaining and mutation testing for KIT and PDGFRA were all negative. About 57.1% (84/147) of patients were CD34-positive, which was lower than GIST (81%) [33] . Other antibody markers were different in these studies; thus it was hard to analyze. Considering the follow-up data from different studies, it is very difficult to reach a persuasive conclusion. However, there is a trend that EGIST is an aggressive group with worse outcome.
In conclusion, we have presented a case of hepatic EGIST diagnosed by US-FNAC. The incidence of EGIST is low, and it has a younger age of diagnosis and large tumor size. The mitotic index can be a prognostic factor; however, tumor size still needs more proof. Furthermore, EGIST can be misdiagnosed for other diseases, and clinicians should take it seriously.
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